Text Module

Share

Program Content

Activities

  • Role of CDK4/6 Inhibitors in HR+/HER2- EBC
    Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 24, 2025

    Expires: January 23, 2026

  • Adjuvant Treatment of HR Positive HER2 Negative EBC
    Integrating the Evidence on Adjuvant Therapy for High-risk HR-Positive/HER2-Negative Early Breast Cancer
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 05, 2025

    Expires: February 04, 2026

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Q Synthesis LLC

ProCE Banner

The American Society of Breast Surgeons Foundation

ProCE Banner